Meeting
2023 ASCO Annual Meeting
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
Authors
Chung-Han Lee
Memorial Sloan Kettering Cancer Center, New York, NY
Chung-Han Lee , Kelly N. Fitzgerald , Martin H Voss , Maria Isabel Carlo , Andrea Knezevic , Laura Peralta , Ying-Bei Chen , Mark Zucker , Robert A Lefkowitz , Eduard Reznik , Neil J. Shah , Colette Ngozi Owens , Deaglan Joseph McHugh , David H Aggen , Andrew Leonard Laccetti , Ritesh R Kotecha , Darren R. Feldman , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03635892
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4537)
DOI
10.1200/JCO.2023.41.16_suppl.4537
Abstract #
4537
Poster Bd #
29
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
First Author: Chung-Han Lee
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2022 ASCO Annual Meeting
IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.
First Author: Anna Saborowski
Poster
2020 Genitourinary Cancers Symposium
A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
First Author: Thomas E. Hutson